|1.||Steyn, D W: 3 articles (01/2007 - 06/2000)|
|2.||Chan, Thomas Y K: 2 articles (07/2014 - 10/2009)|
|3.||Sequeira, Reginald P: 2 articles (03/2014 - 11/2003)|
|4.||Damanhori, Awatif H H: 2 articles (03/2014 - 11/2003)|
|5.||von Dadelszen, Peter: 2 articles (01/2013 - 01/2007)|
|6.||Khalil, Asma: 2 articles (03/2009 - 01/2008)|
|7.||Jauniaux, Eric: 2 articles (03/2009 - 01/2008)|
|8.||Harrington, Kevin: 2 articles (03/2009 - 01/2008)|
|9.||Magee, Laura A: 2 articles (01/2007 - 01/2004)|
|10.||El-Mas, Mahmoud M: 2 articles (10/2004 - 02/2004)|
|1.||Hypertension (High Blood Pressure)
03/01/1976 - "Thus, the beneficial effect of this agent on the myocardial circulation, together with its lack of any detrimental effect on the cardiac function suggest that methyldopa may be an effective agent for the control of hypertension."
06/01/1977 - "The hypotensive effect of methyldopa was similar to its action in non-pregnant individuals and greatly reduced the frequency of severe hypertension occurring antenatally and in labour. "
01/01/2014 - "Alternative drugs seem better than methyldopa for reducing the risk of severe hypertension (11 trials, 638 women; RR (random-effects) 0.54; 95% CI 0.30 to 0.95; RD -0.11 (-0.20 to -0.02); NNTH 7 (5 to 69)). "
01/01/2007 - "Beta blockers seem better than methyldopa for reducing the risk of severe hypertension (10 trials, 539 women, RR 0.75 (95 % CI 0.59 to 0.94); RD -0.08 (-0.14 to 0.02); NNT 12 (6 to 275)). "
01/01/1991 - "This study has been performed to assess the effect of methyldopa (MD) therapy in pregnancy hypertension on the neonatal adaptation. "
03/01/2009 - "In preeclampsia, vascular stiffness was significantly improved by antihypertensive treatment with alpha methyldopa, but remained higher than in normotensive controls."
04/01/2002 - "To evaluate the efficacy of methyldopa in the treatment of mild pre-eclampsia, to prevent its progress and to investigate its effect on the pregnancy outcomes. "
04/01/2002 - "Methyldopa can prevent the progress of the mild pre-eclampsia to severe pre-eclampsia, without affecting the maturity, birthweight or the neonatal outcomes."
04/01/2002 - "Methyldopa versus no drug treatment in the management of mild pre-eclampsia."
02/01/1987 - "However, 75% of the superimposed pre-eclampsia occurred antepartum in the placebo group, while 80% of the methyldopa-treated group developed superimposed pre-eclampsia intrapartum. "
|3.||Cardiomegaly (Heart Hypertrophy)
07/01/1982 - "Alpha methyldopa has been shown to modify left ventricular mass and normalize mitochondria/myofibrils volume ratio in spontaneously hypertensive rats (SHR) when administered during the stage of developing cardiac hypertrophy (Tomanek et al., Cardiovas Res 23: 173, 1979). "
01/01/1980 - "Treatment with methyldopa reduced the SHR arterial blood pressure (average 57 mm Hg) and reversed the cardiac hypertrophy toward normal. "
03/01/1979 - "The effects of alpha-methyldopa on cardiac hypertrophy in spontaneously hypertensive rats: ultrastructural, stereological, and morphometric analysis."
10/22/1979 - "Reversal of cardiac hypertrophy by prolonged treatment with methyldopa (range 3 to 6 weeks) during the established phase of spontaneous hypertension normalized arterial blood pressure and improved ventricular pumping ability. "
02/01/1990 - "These results suggest that the ANP release from the left atrium is chronically stimulated in adult SHR, and that a decrease in plasma ANP concentration by methyldopa treatment is, in part, associated with the decline of ANP release from the heart due to the reductions of blood pressure and cardiac hypertrophy."
08/01/2001 - "Treatment with methyldopa normalized SBP, improved CCR and proteinuria and was associated with an increase in UNO(3). "
06/01/2012 - "A total of 150 consecutive pregnant women without proteinuria and with physician-recorded systolic BP of 140-160 mmHg and/or diastolic BP of 90-105 mmHg on two occasions ≥6 h apart between 20 and 38 weeks of gestation were randomly allocated to receive either labetalol or methyldopa (50 patients each) plus standard care (treatment group) or only standard care (50 patients) (control group). "
05/01/1992 - "After cessation of methyldopa treatment, the sigmoid findings, blood pressure, and proteinuria were improved, suggesting that methyldopa not only induced the acute colitis but also worsened the nephrotic syndrome in this patient."
01/01/2014 - "There is also a reduction in the overall risk of developing proteinuria/pre-eclampsia when beta blockers and calcium channel blockers considered together are compared with methyldopa (11 trials, 997 women; RR 0.73; 95% CI 0.54 to 0.99). "
02/01/2000 - "Methyldopa was the antihypertensive used most frequently for the treatment of mild to moderate hypertension (diastolic blood pressure between 90 and 109 mmHg), while intravenous dihydralazine was preferred in severe hypertension (diastolic blood pressure > or = 110 mmHg and proteinuria > or = +2). "
01/01/1985 - "These results are discussed in the context of other studies on the mode of action of methyldopa in eliciting an autoimmune anemia in man treated therapeutically with this drug."
01/01/2008 - "The present observations disclose a novel action of methyldopa, which may well contribute to drug-induced anemia."
01/01/2008 - "Side effects of methyldopa include anemia, which could result from decreased formation or accelerated death of circulating erythrocytes. "
09/01/1967 - "Anemia, positive lupus and rheumatoid factors with methyldopa. "
05/01/1988 - "After the initial evaluation revealed anemia and a 3+ positive Coombs' test, a diagnosis of methyldopa-induced hemolytic anemia was entertained. "
|5.||Clonidine (ST 155)
|1.||Drug Therapy (Chemotherapy)
|3.||Bed Rest (Bedrest)